ABL1 and acute lymphoblastic leukemia: In the Ph-like B-ALL subtype, MLN0128 enhances efficacy of dasatinib (in samples driven by ABL or PDGFR fusions) or ruxolitinib (in samples driven by active JAK signaling) (26, 27).